Almirall, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: $2B

Website

Clinical Trials

Efficacy and Safety of Tildrakizumab in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Who Are Non-Responders to Dimethyl Fumarate Therapy

Phase 4

Completed

Conditions: Plaque Psoriasis

Interventions: Drug: Dimethyl fumarate (DMF) standard scheme
Drug: Dimethyl fumarate (DMF) simplified scheme
Drug: Tildrakizumab

First Posted Date: 2020-02-11

Last Posted Date: 2022-05-27

Lead Sponsor: Almirall, S.A.

Target Recruit Count: 190

Registration Number: NCT04263610

Locations: 🇩🇪
Investigator Site 3, Augsburg, Germany
🇬🇧
Investigator Site 2, London, United Kingdom
🇬🇧
Investigator Site 1, Bristol, United Kingdom

Efficacy and Safety of Tildrakizumab 100 Milligrams (mg) in Participants With Moderate-Severe Chronic Plaque Psoriasis and Its Impact on Their Quality of Life (TRIBUTE)

Phase 4

Completed

Conditions: Plaque Psoriasis

Interventions: Drug: Tildrakizumab 100 mg Solution for Injection

First Posted Date: 2020-01-18

Last Posted Date: 2023-03-03

Lead Sponsor: Almirall, S.A.

Target Recruit Count: 178

Registration Number: NCT04229836

Locations: 🇪🇸
Investigator Site 8, Madrid, Spain
🇪🇸
Investigator Site 9, Madrid, Spain
🇮🇹
Investigator Site 10, Novara, Italy

and more 19 locations

Observational Study of Tildrakizumab in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical Practice

Completed

Conditions: Plaque Psoriasis

Interventions: Drug: Tildrakizumab

First Posted Date: 2019-12-18

Last Posted Date: 2024-07-08

Lead Sponsor: Almirall, S.A.

Target Recruit Count: 331

Registration Number: NCT04203693

Locations: 🇳🇱
Investigational site 1, Breda, Netherlands
🇮🇹
Investigational site 5, Roma, Italy
🇩🇪
Investigational site 13, Berlin, Germany

and more 11 locations

A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on AK on Face or Scalp

Phase 3

Completed

Conditions: Actinic Keratoses

Interventions: Drug: KX2-391 Ointment 1%
Drug: Placebo

First Posted Date: 2017-09-18

Last Posted Date: 2021-04-13

Lead Sponsor: Almirall, S.A.

Target Recruit Count: 351

Registration Number: NCT03285477

Locations: 🇺🇸
Coastal Clinical Research, Inc., Mobile, Alabama, United States
🇺🇸
Olympian Clinical Research, Clearwater, Florida, United States
🇺🇸
Arlington Dermatology, Arlington Heights, Illinois, United States

and more 27 locations

A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on Actinic Keratosis on Face or Scalp (AK004)

Phase 3

Completed

Conditions: Actinic Keratosis

Interventions: Drug: Placebo
Drug: KX2-391 Ointment 1%

First Posted Date: 2017-09-18

Last Posted Date: 2021-03-10

Lead Sponsor: Almirall, S.A.

Target Recruit Count: 351

Registration Number: NCT03285490

Locations: 🇺🇸
Alliance Dermatology, Phoenix, Arizona, United States
🇺🇸
Burke Pharmaceutical Research, Hot Springs, Arkansas, United States
🇺🇸
Activmed Practices & Research, Inc, Portsmouth, New Hampshire, United States

and more 26 locations

Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris

Phase 4

Completed

Conditions: Acne Vulgaris

Interventions: Drug: dapsone gel

First Posted Date: 2016-11-09

Last Posted Date: 2020-03-03

Lead Sponsor: Almirall, S.A.

Target Recruit Count: 100

Registration Number: NCT02959970

Locations: 🇺🇸
Redwood Family Dermatology, Santa Rosa, California, United States
🇺🇸
Skin Specialists, PC, Omaha, Nebraska, United States
🇺🇸
DermResearch, LLC, Austin, Texas, United States

and more 17 locations

Study of the Effects of the Organism on Monomethyl Fumarate (MMF) After the Administration of LAS41008

Phase 1

Completed

Conditions: Psoriasis

Interventions: Drug: LAS41008 120 mg / Fumaderm® 120 mg

First Posted Date: 2016-11-04

Last Posted Date: 2016-12-22

Lead Sponsor: Almirall, S.A.

Target Recruit Count: 32

Registration Number: NCT02955693

Locations: 🇬🇧
Almirall Investigational Site #1, London, Harrow, United Kingdom

Activity & Safety Study of KX2-391 Ointment in Participants With Actinic Keratosis on the Face or Scalp

Phase 2

Completed

Conditions: Actinic Keratosis

Interventions: Drug: 50 mg of KX2-391 Ointment 1%

First Posted Date: 2016-07-20

Last Posted Date: 2021-04-14

Lead Sponsor: Almirall, S.A.

Target Recruit Count: 168

Registration Number: NCT02838628

Locations: 🇺🇸
International Dermatology Research, Miami, Florida, United States
🇺🇸
The Center for Skin Research, Houston, Texas, United States
🇺🇸
Clinical Trials of Texas, Inc., San Antonio, Texas, United States

and more 13 locations

A Multi-Center Open-Label Evaluation of the Safety of Sarecycline Tablets in the Treatment of Acne Vulgaris

Phase 3

Completed

Conditions: Acne Vulgaris

Interventions: Drug: Sarecycline

First Posted Date: 2015-04-09

Last Posted Date: 2019-02-01

Lead Sponsor: Almirall, S.A.

Target Recruit Count: 490

Registration Number: NCT02413346

Locations: 🇺🇸
Actavis Investigational Study Site #212, West Jordan, Utah, United States
🇺🇸
Actavis Investigational Study Site #129, Encino, California, United States
🇺🇸
Actavis Investigational Study Site #113, South Bend, Indiana, United States

and more 52 locations

Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne

Phase 3

Completed

Conditions: Acne Vulgaris

Interventions: Drug: Sarecycline
Drug: Placebo

First Posted Date: 2014-12-23

Last Posted Date: 2019-02-01

Lead Sponsor: Almirall, S.A.

Target Recruit Count: 1034

Registration Number: NCT02322866

Locations: 🇺🇸
Warner Chilcott Research Site (Site #256), Philadelphia, Pennsylvania, United States
🇺🇸
Warner Chilcott Research Site (Site #249), Miami, Florida, United States
🇺🇸
Warner Chilcott Research Site (Site #254), San Diego, California, United States

and more 54 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy